{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"100","value":"700"}]}],"title":"Matched Related Donors (MRD) n=38 - CD3+ Tcells/uL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"150","value":"550"}]}],"title":"Matched Unrelated Donors(MUD) n=53 - CD3+Tcells/uL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"200","value":"500"}]}],"title":"Haploidentical related (HAPLO) n=33 -CD3+Tcells/uL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30","value":"225"}]}],"title":"Matched Related Donors (MRD) n=38 - CD4+ Tcells/uL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20","value":"140"}]}],"title":"Matched Unrelated Donors (MUD) n=53 -CD4+Tcells/uL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55","value":"150"}]}],"title":"Haploidentical related (HAPLO) n=33 -CD4+Tcells/uL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"100","value":"420"}]}],"title":"Matched Related Donors (MRD) n=38 - CD8+ Tcells/uL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"150","value":"350"}]}],"title":"Matched Unrelated Donors (MUD) n=53 -CD8+Tcells/uL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"150","value":"300"}]}],"title":"Haploidentical related (HAPLO) n=33 -CD8+Tcells/uL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"}],"units":"Participants"}],"description":"Evaluate immune recovery following this reduced intensity allogeneic immunotherapy. Quantification of CD3+, CD4+, and CD8+ T cells was performed by flow cytometry on fresh peripheral blood at approximately 1 month before transplantation and then 1.5, 3, 6, and 12 months after transplantation. The immune recovery rates of the CD3+, CD4+, and CD8+ T cells in the MRD, MUD, and HAPLO groups were compared by performing an analysis of variance at each time point after transplantation. The median T cell counts at 12 months for each type of cell are reported by donor type.","dispersionType":"Standard Deviation","groups":[{"description":"Non-myeloablative Stem Cell Transplant (SCT): Donor will receive Granulocyte colony-stimulating factor (G-CSF) 8 mcg/kg/d subcutaneously twice daily for 4 days, until pheresis is completed or until white blood cells \\> 100,000. Recipients will be premedicated with Benadryl 50 mg intravenously (IV) or orally (PO), and acetaminophen 650 mg PO (or hydrocortisone 50-100 mg IV on first day). The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. The Peripheral Blood Stem Cells (PBSCs) will be infused over 2-4 days. Participant evaluations will occur 2 times per week by physical exam for toxicity through day 45.","id":"OG000","title":"Cohort A & B- Lymphoid & Myeloid Disease"}],"paramType":"MEAN","populationDescription":"All subjects with complete response. Cohort A (n=62) had acute or chronic leukemia (ALL or CLL), lymphoma, or myeloma. Cohort B (n=62) had acute or chronic myeloid leukemia (AML or CML), myelodysplastic disorder or myeloproliferative disorder. Analysis by type of donor (Matched Unrelated Donor; Matched Related Donor; Haplo-identical).","reportingStatus":"POSTED","timeFrame":"1 year","title":"Immune Recovery","type":"SECONDARY","unitOfMeasure":"T cells/μL"}